New RSV drug for babies shows promise in phase 3 trial

NCT ID NCT07402512

Recruiting now Symptom relief Sponsor: Simcere Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests an oral medicine called deurremidevir in infants and young children (1 month to 3 years old) with RSV infection. The goal is to see if it can shorten the time until symptoms like wheezing and rapid breathing go away. About 498 children will receive either the drug or a placebo for 5 days. If successful, it could offer a new way to help babies recover faster from RSV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deurremidevir hydrobromide (oral suspension)
What this could lead to: If it works, this could provide a fast-acting treatment to ease RSV symptoms in infants and young children, reducing hospital stays and breathing distress.
What could go wrong: This is still a placebo-controlled trial, so the drug may not prove better than placebo. Side effects in very young children are unknown, and results may not apply to all RSV cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTION

Contacts and locations

Locations

Hunan Children's Hospital
RECRUITING

Changsha, Hunan, China
Shulan(hangzhou)Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
The First Affiliated Hospital Of Xiamen University
RECRUITING

Xiamen, Fujian, China
West China Second University Hospital Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.